Shockwave Medical to bring IVL to the Chinese market

1233

Shockwave Medical has announced that the company has signed an agreement to form a joint venture with Genesis MedTech Group to introduce its intravascular lithotripsy (IVL) technology to the Chinese market. Together, Shockwave and Genesis strive to bring coronary and peripheral IVL products to patients in mainland China, the companies said in a press release.

“Shockwave is a pioneer in their field and our partnership will be of long-term strategic significance not only for Genesis MedTech, but also for the medical community in China,” said Warren Wang, chairman and chief executive officer of Genesis MedTech International. “We share Shockwave’s passion for developing technologies to serve unmet medical needs and are confident that together we can help many patients in China who suffer from calcified arterial disease.”

“This joint venture represents another step in the continuation of our strategy to ensure that patients globally have access to IVL and to do so with a strong, local presence. We are pleased to have a partner with such a solid, established track record in developing and commercialising innovative technologies in China,” said Doug Godshall, president and chief executive officer of Shockwave Medical. “We look forward to joining forces with Warren and his team as we work together to bring IVL to the large and growing Chinese interventional market.”

According to the agreement, the new joint venture will be named Genesis Shockwave Private Limited and enables the commercialisation of both imported Shockwave-branded IVL products as well as IVL products that are locally developed, manufactured, and branded by Genesis Shockwave Private Limited. The creation of the joint venture is subject to the satisfaction of certain closing conditions, including the approval of relevant government authorities in China.

Shockwave IVL received pre-market approval for the treatment of severely calcified coronary artery disease from the US Food and Drug Administration (FDA) in February 2021.


LEAVE A REPLY

Please enter your comment!
Please enter your name here